Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy; lipid metabolism as a novel biomarker to predict prostate cancer progression ; phase 3, double-blind randomized clinical trial
Latest Information Update: 27 Oct 2023
At a glance
- Drugs Atorvastatin (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms ESTO2
Most Recent Events
- 10 Sep 2019 Status changed from not yet recruiting to recruiting.
- 22 Jul 2019 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT04026230)
- 20 Feb 2019 New trial record